Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) was founded in 2003, headquartered in Rehovot, Israel, with 68 full-time employees (2017). It is a clinical-stage professional pharmaceutical company dedicated to the development and sales of its patented minocycline foam Preparation (minocycline foam), used to treat skin diseases such as acne and impetigo.
Foamix Pharmaceuticals (FOMX):
Foamix Pharmaceuticals Ltd. is a clinical-stage professional pharmaceutical company dedicated to the development and sales of foam-based formulations for the treatment of acne, pustules and other skin diseases. The company’s main product candidates are FMX101 and FMX102. The former is a drug that has completed phase II clinical trials for the treatment of moderate to severe acne, and the latter is a drug that has completed the treatment of methicillin-resistant Staphylococcus aureus II caused by impetigo. Drugs in clinical trials.
In addition, FMX103 is a new version of FMX101 for the treatment of rosacea; FDX104 is used for the treatment of rashes caused by chemotherapy and various skin indications, including atopic dermatitis, psoriasis, genital warts and actinic keratosis, And treatment of herpes and fungal infections.
Foamix is currently engaged in research in Germany, the United States and Israel, and has reached cooperation agreements with Bayer HealthCare AG, Merz Pharmaceuticals, LLC, and Actavis plc in Germany.